Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 480	$ 65,916
General and administrative	166,742	198,200
Total operating expenses	167,222	264,116
Loss from operations	(167,222)	(264,116)
Other income (expense):
Interest expense, net	(234,709)	(394,278)
Reimbursement for expenses - related party	12,538	72,246
Change in fair value of derivative on debt	2,476	(19,896)
Loss on extinguishment / conversion of debt	(88,258)
Total other expense	(307,953)	(341,928)
Net loss before non-controlling interests	(475,175)	(606,044)
Net loss attributable to non-controlling interests	(66,499)	(80,625)
Net loss attributable to Oncotelic Therapeutics, Inc.	$ (408,676)	$ (525,419)
Basic net loss per share attributable to common stock	$ (0.00)	$ (0.00)
Diluted net loss per share attributable to common stock	$ (0.00)	$ (0.00)
Basic weighted average common stock outstanding	399,378,572	392,359,380
Diluted weighted average common stock outstanding	399,378,572	392,359,380